SARASOTA, Fla., Nov. 9, 2021 /PRNewswire/ -- INVO
Bioscience, Inc. (NASDAQ: INVO), a medical device company
focused on commercializing the world's only in vivo Culture System
(IVC), INVOcell®, an effective and affordable treatment for
patients diagnosed with infertility, will report financial results
for its third quarter 2021, ended September
30, 2021, after the market close on Monday, November 15, 2021. The Company has
scheduled a conference call that same day, Monday, November 15, 2021, at 4:30 pm ET, to review the results.
Third Quarter 2021 Conference Call Details
Date and Time: Monday, November 15, 2021, at
4:30 pm ET
Call-in Information: Interested parties can access
the conference call by dialing 833-756-0861 or 412-317-5751.
Live Webcast Information: Interested parties can
access the conference call via a live webcast, which is available
in the Investor Relations section of the Company's website at
https://www.invobioscience.com/investors/ or
https://www.webcaster4.com/Webcast/Page/2162/43563.
Replay: A teleconference replay of the call will be
available through November 22, 2021
at 877-344-7529 or 412-317-0088, confirmation # 10161468. A webcast
replay will be available in the Investor Relations section of the
Company's website at https://www.invobioscience.com/investors/ for
90 days.
About INVO Bioscience
We are a medical device company focused on creating simplified,
lower-cost treatments for patients diagnosed with infertility. Our
solution, the INVO® Procedure, is a revolutionary in vivo method of
vaginal incubation that offers patients a more natural and intimate
experience. Our lead product, the INVOcell®, is a patented medical
device used in infertility treatment and is considered an Assisted
Reproductive Technology (ART). The INVOcell® is the first
Intravaginal Culture (IVC) system in the world used for the natural
in vivo incubation of eggs and sperm during fertilization and early
embryo development, as an alternative to traditional In Vitro
Fertilization (IVF) and Intrauterine Insemination (IUI). Our
mission is to increase access to care and expand fertility
treatment across the globe with a goal to lower the cost of care
and increase the availability of care. For more information, please
visit http://invobioscience.com/
Safe Harbor Statement
This release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
The Company invokes the protections of the Private Securities
Litigation Reform Act of 1995. All statements regarding our
expected future financial position, results of operations, cash
flows, financing plans, business strategies, products and services,
competitive positions, growth opportunities, plans and objectives
of management for future operations, as well as statements that
include words such as "anticipate," "if," "believe," "plan,"
"estimate," "expect," "intend," "may," "could," "should," "will,"
and other similar expressions are forward-looking statements. All
forward-looking statements involve risks, uncertainties and
contingencies, many of which are beyond our control, which may
cause actual results, performance, or achievements to differ
materially from anticipated results, performance, or achievements.
Factors that may cause actual results to differ materially from
those in the forward-looking statements include those set forth in
our filings at www.sec.gov. We are under no obligation to
(and expressly disclaim any such obligation to) update or alter our
forward-looking statements, whether as a result of new information,
future events or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/invo-bioscience-to-report-third-quarter-2021-financial-results-on-monday-november-15-2021-301420346.html
SOURCE INVO Bioscience, Inc.